Tolvaptan for treatment of iatrogenic hyponatremia [PDF]
openaire +3 more sources
The Role of Baseline Total Kidney Volume Growth Rate in Predicting Tolvaptan Efficacy for ADPKD Patients: A Feasibility Study. [PDF]
Dev H+12 more
europepmc +1 more source
MP340LONG-TERM RENOPROTECTIVE EFFECTS OF TOLVAPTAN IN PATIENTS WITH ACUTE HEART FAILURE [PDF]
Tatsufumi Oka+7 more
openalex +1 more source
Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy. [PDF]
Lohrmann E+12 more
europepmc +1 more source
Wyatt CM, Le Meur Y. REPRISE: tolvaptan in advanced polycystic kidney disease. Kidney Int. 2018;93:292–295 [PDF]
openalex +1 more source
Tolvaptan for the Treatment of Elephantiasis Nostras Verrucosa
Yuko Eda+3 more
openaire +4 more sources
Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update. [PDF]
Gittus M+12 more
europepmc +1 more source
Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease [PDF]
James J. Beaudoin+6 more
openalex +1 more source
The prospect of novel orphan therapeutic protocol for TSC2/PKD1 contiguous gene syndrome: a case report. [PDF]
Agavriloaei BD+6 more
europepmc +1 more source